Suhexiang Pill for Acute Ischemic Stroke: A Registry Study
SUNRISE
1 other identifier
observational
1,000
1 country
2
Brief Summary
The primary purpose of this study is to investigate the effectiveness and safety of the Suhexiang Pill for patients with acute ischemic stroke in real-world settings.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2023
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 24, 2023
CompletedFirst Posted
Study publicly available on registry
April 27, 2023
CompletedStudy Start
First participant enrolled
June 1, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2024
CompletedJune 11, 2024
June 1, 2024
1.6 years
March 24, 2023
June 10, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Proportion of patients independent
Proportion of patients independent is defined as the modified Rankin Scale score of 0, 1, or 2.
90 days
Secondary Outcomes (3)
National Institute of Health Stroke Scale
The change from baseline to day 10 or discharge.
Glasgow Coma Scale
The change from baseline to day 10 or discharge.
Patient reported outcome
At day 10 or discharge.
Interventions
Suhexiang Pill is an approved traditional Chinese patent medicine.
Eligibility Criteria
Patients diagnosed with Acute ischemic stroke.
You may qualify if:
- Acute ischemic stroke within 7 days of symptom onset.
- Age ≥ 18
- Patient who has received Suhexiang Pill treatment
- Patient or legally authorized representative has signed informed consent.
You may not qualify if:
- Be allergic to Suhexiang Pill
- Known to be pregnant or breastfeeding.
- With conditions that render outcomes or follow-up unlikely to be assessed.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Dongzhimen Hospital
Beijing, Beijing Municipality, 100700, China
Dongzhimen Hospital
Beijing, Beijing Municipality, 100700, China
Related Publications (1)
Lai X, Xiong X, Jia Q, Liu T, Yang Z, Zhang C, Kong L, Cao K, Dong T, Fang C, Ge J, Dong L, Zong Z, Chen S, Ma Y, Bai X, Wu D, Xie Y, Zhang M, Wang Y, Jiang G, Song D, Wang Y, Gui C, Geng Q, Gao Y; SUNRISE study investigators. Suhexiang pill for acute ischemic stroke in real-world practice setting (SUNRISE): protocol of a multicenter registry. BMC Complement Med Ther. 2025 Jan 28;25(1):30. doi: 10.1186/s12906-025-04762-9.
PMID: 39875901DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 1 Year
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
March 24, 2023
First Posted
April 27, 2023
Study Start
June 1, 2023
Primary Completion
December 31, 2024
Study Completion
December 31, 2024
Last Updated
June 11, 2024
Record last verified: 2024-06